



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

A*STAR's SINGAPORE IMMUNOLOGY NETWORK IS THE FIRST GENEGO CENTER OF EXCELLENCE IN ASIA

St. Joseph, Michigan, December 10th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that A*STAR's Singapore Immunology Network (SIgN) has become a certified GeneGo Center of Excellence (COE). SIgN researchers will have access to GeneGo's MetaCore, training and advanced support. SIgN COE will provide a pathway analysis environment for all SIgN researchers.

“We are excited to work with SIgN, one of the premium life sciences research institutes in the world, said Julie Bryant, Vice President of Business Development at GeneGo. “We look forward to building closer relationships with SIgN investigators and growing the number of MetaCore users in Singapore.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.1™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.